NICE is unable to make a recommendation on mepolizumab (Nucala) for treating eosinophilic granulomatosis with polyangiitis in people 6 years and over because GSK did not provide an evidence submission. We will review this decision if the company decides to make a submission.

Guidance development process

How we develop NICE technology appraisal guidance